Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2025 | 03-2024 | 03-2023 | 03-2022 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -356,734 | 4,231,206 | -1,115,463 | -924,116 | -900,233 |
| Depreciation Amortization | 14,071 | 22,036 | 18,857 | 5,932 | N/A |
| Accounts payable and accrued liabilities | -18,168 | 22,684 | 4,359 | 15,403 | 3,752 |
| Other Working Capital | -77,046 | 19,035 | 6,345 | 15,719 | 71,938 |
| Other Operating Activity | -401,574 | -5,060,229 | 242,509 | 209,333 | 272,405 |
| Operating Cash Flow | $-839,451 | $-765,268 | $-843,393 | $-677,729 | $-552,138 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -2,101,521 | N/A | N/A | N/A | N/A |
| PPE Investments | -4,599 | -1,382 | -12,690 | -17,436 | -5,806 |
| Net Acquisitions | 339,750 | 5,196,413 | -6,706 | -39 | N/A |
| Sale Of Investment | N/A | N/A | 114,561 | 320,170 | N/A |
| Other Investing Activity | 79 | 8,592 | -139,434 | 600 | -25,896 |
| Investing Cash Flow | $-1,766,291 | $5,203,623 | $-44,269 | $303,295 | $-31,702 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 159,899 | 36,400 | N/A |
| Debt Repayment | -51,979 | -29,158 | -29,452 | -21,590 | N/A |
| Common Stock Issued | 163,407 | 493,825 | 382,838 | 412 | 455,756 |
| Common Stock Repurchased | -1,293,232 | -41 | N/A | N/A | N/A |
| Dividend Paid | N/A | -6,000 | N/A | N/A | N/A |
| Other Financing Activity | -37,990 | -39,262 | -13,823 | 291,570 | 508 |
| Financing Cash Flow | $-1,219,794 | $419,364 | $499,462 | $306,792 | $456,264 |
| Exchange Rate Effect | 747 | 616 | 6,281 | N/A | N/A |
| Beginning Cash Position | 6,550,450 | 1,692,115 | 2,074,034 | 2,141,676 | 2,269,252 |
| End Cash Position | 2,725,661 | 6,550,450 | 1,692,115 | 2,074,034 | 2,141,676 |
| Net Cash Flow | $-3,824,789 | $4,858,335 | $-381,919 | $-67,642 | $-127,576 |
| Free Cash Flow | |||||
| Operating Cash Flow | -839,451 | -765,268 | -843,393 | -677,729 | -552,138 |
| Capital Expenditure | -4,599 | -1,382 | -12,690 | -17,436 | -5,806 |
| Free Cash Flow | -844,050 | -766,650 | -856,083 | -695,165 | -557,944 |